GeNeuro SA

GNRO

Company Profile

  • Business description

    GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

  • Contact

    3 chemin du Pre-Fleur
    Plan-les-Ouates
    Geneva1228
    CHE

    T: +41 225524800

    https://www.geneuro.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    19

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.2090.501.08%
CAC 407,770.48176.612.33%
DAX 4023,086.65589.672.62%
Dow JONES (US)41,317.43564.471.39%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,977.73266.991.51%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,327.89179.291.48%
S&P 5005,686.6782.531.47%
S&P/ASX 2008,238.0092.401.13%
SSE Composite Index3,279.037.62-0.23%

Market Movers